The Underlying Mechanism of Prodromal PD: Insights from the Parasympathetic Nervous System and the Olfactory System

Overview

Journal Transl Neurodegener

Publisher Biomed Central

Date 2017 Feb 28

PMID 28239455

Citations 11

Authors

Shu-Ying Liu

Piu Chan

A Jon Stoessl

Affiliations

Soon will be listed here.

Abstract

Neurodegeneration of Parkinson's disease (PD) starts in an insidious manner, 30-50% of dopaminergic neurons have been lost in the substantia nigra before clinical diagnosis. Prodromal stage of the disease, during which the disease pathology has started but is insufficient to result in clinical manifestations, offers a valuable window for disease-modifying therapies. The most focused underlying mechanisms linking the pathological pattern and clinical characteristics of prodromal PD are the prion hypothesis of alpha-synuclein and the selective vulnerability of neurons. In this review, we consider the two potential portals, the vagus nerve and the olfactory bulb, through which abnormal alpha-synuclein can access the brain. We review the clinical, pathological and neuroimaging evidence of the parasympathetic nervous system and the olfactory system in the neurodegenerative process and using the two systems as models to discuss the internal homogeneity and heterogeneity of the prodromal stage of PD, including both the clustering and subtyping of symptoms and signs. Finally, we offer some suggestions on future directions for imaging studies in prodromal Parkinson's disease.

Citing Articles

Disruption of Dopamine Homeostasis Associated with Alteration of Proteins in Synaptic Vesicles: A Putative Central Mechanism of Parkinson's Disease Pathogenesis.

Jin X, Si X, Lei X, Liu H, Shao A, Li L Aging Dis. 2023; 15(3):1204-1226.

PMID: 37815908 PMC: 11081171. DOI: 10.14336/AD.2023.0821-2.

The role of the microbiota-gut-brain axis in long-term neurodegenerative processes following traumatic brain injury.

Chiu L, Anderton R Eur J Neurosci. 2022; 57(2):400-418.

PMID: 36494087 PMC: 10107147. DOI: 10.1111/ejn.15892.

Impact of Gastrointestinal Symptoms on Health-Related Quality of Life in an Australian Parkinson's Disease Cohort.

Kenna J, Bakeberg M, Abonnel M, Mastaglia F, Anderton R Parkinsons Dis. 2022; 2022:4053665.

PMID: 36466568 PMC: 9718626. DOI: 10.1155/2022/4053665.

Imaging of α-Synuclein Aggregates in a Rat Model of Parkinson's Disease Using Raman Microspectroscopy.

Sevgi F, Brauchle E, Carvajal Berrio D, Schenke-Layland K, Casadei N, Salker M Front Cell Dev Biol. 2021; 9:664365.

PMID: 34568310 PMC: 8461246. DOI: 10.3389/fcell.2021.664365.

Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis.

Walczak-Nowicka L, Herbet M Int J Mol Sci. 2021; 22(17).

PMID: 34502198 PMC: 8430571. DOI: 10.3390/ijms22179290.

References

Sengoku R, Matsushima S, Bono K, Sakuta K, Yamazaki M, Miyagawa S . Olfactory function combined with morphology distinguishes Parkinson's disease. Parkinsonism Relat Disord. 2015; 21(7):771-7. DOI: 10.1016/j.parkreldis.2015.05.001. View

Haberly L . Parallel-distributed processing in olfactory cortex: new insights from morphological and physiological analysis of neuronal circuitry. Chem Senses. 2001; 26(5):551-76. DOI: 10.1093/chemse/26.5.551. View

Marras C, Lang A, Austin P, Lau C, Urbach D . Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. Mov Disord. 2016; 31(8):1243-7. DOI: 10.1002/mds.26670. View

Adler C, Beach T . Neuropathological basis of nonmotor manifestations of Parkinson's disease. Mov Disord. 2016; 31(8):1114-9. PMC: 4981515. DOI: 10.1002/mds.26605. View

Hubbard P, Esiri M, Reading M, McShane R, Nagy Z . Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat. 2007; 211(1):117-24. PMC: 2375794. DOI: 10.1111/j.1469-7580.2007.00748.x. View

Westermann B, Wattendorf E, Schwerdtfeger U, Husner A, Fuhr P, Gratzl O . Functional imaging of the cerebral olfactory system in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007; 79(1):19-24. DOI: 10.1136/jnnp.2006.113860. View

Kingsbury A, Bandopadhyay R, Silveira-Moriyama L, Ayling H, Kallis C, Sterlacci W . Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov Disord. 2010; 25(15):2508-15. DOI: 10.1002/mds.23305. View

Wattendorf E, Welge-Lussen A, Fiedler K, Bilecen D, Wolfensberger M, Fuhr P . Olfactory impairment predicts brain atrophy in Parkinson's disease. J Neurosci. 2009; 29(49):15410-3. PMC: 6666111. DOI: 10.1523/JNEUROSCI.1909-09.2009. View

Attems J, Walker L, Jellinger K . Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol. 2014; 127(4):459-75. DOI: 10.1007/s00401-014-1261-7. View

10.

von Coelln R, Shulman L . Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. Curr Opin Neurol. 2016; 29(6):727-734. DOI: 10.1097/WCO.0000000000000384. View

11.

Marras C, Schule B, Schuele B, Munhoz R, Rogaeva E, Langston J . Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology. 2011; 77(4):325-33. PMC: 3140802. DOI: 10.1212/WNL.0b013e318227042d. View

12.

Berg D, Postuma R, Adler C, Bloem B, Chan P, Dubois B . MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015; 30(12):1600-11. DOI: 10.1002/mds.26431. View

13.

He Q, Yu W, Wu J, Chen C, Lou Z, Zhang Q . Intranasal LPS-mediated Parkinson's model challenges the pathogenesis of nasal cavity and environmental toxins. PLoS One. 2013; 8(11):e78418. PMC: 3826714. DOI: 10.1371/journal.pone.0078418. View

14.

Valldeoriola F, Gaig C, Muxi A, Navales I, Paredes P, Lomena F . 123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations. J Neurol. 2011; 258(6):1126-32. PMC: 3101340. DOI: 10.1007/s00415-010-5896-6. View

15.

Sauerbier A, Jenner P, Todorova A, Chaudhuri K . Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord. 2015; 22 Suppl 1:S41-6. DOI: 10.1016/j.parkreldis.2015.09.027. View

16.

Mirelman A, Alcalay R, Saunders-Pullman R, Yasinovsky K, Thaler A, Gurevich T . Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Mov Disord. 2015; 30(7):981-6. PMC: 4478229. DOI: 10.1002/mds.26213. View

17.

Goldstein D, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y . Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord. 2008; 14(8):600-7. PMC: 2650101. DOI: 10.1016/j.parkreldis.2008.01.010. View

18.

Ruffmann C, Parkkinen L . Gut Feelings About α-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?. Mov Disord. 2016; 31(2):193-202. PMC: 4755164. DOI: 10.1002/mds.26480. View

19.

Li J, Englund E, Holton J, Soulet D, Hagell P, Lees A . Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. 2008; 14(5):501-3. DOI: 10.1038/nm1746. View

20.

Brettschneider J, Del Tredici K, Lee V, Trojanowski J . Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015; 16(2):109-20. PMC: 4312418. DOI: 10.1038/nrn3887. View